PhRMA Continues Critique of ICER Drug Pricing Studies

The Pharmaceutical Research and manufacturers of America (PhRMA) have repeatedly spoken out against the cost-effectiveness studies published by the Institute for Clinical and Economic Review (ICER) and has recently publicized its own four pointed list of recommendations to ICER. Read more here. (Source: Joe Cantlupe, BioPharma DIVE, 9/29/16)

You might also be interested in:

Trump's "Buy American" Executive Order Could Raise Drug Prices 08/06/2020
Robert Dubois, MD, PhD, Steps in as Interim President and CEO… 09/01/2020
Patient Drug Costs Increased as Health Plans Promote… 08/07/2020
[Webinar] How can VA/HTA Inform Policy Interventions and… 10/15/2020
What Does $11M in Donations to Congress Buy Pharma? 08/12/2020
AHRQ’s Registries User Guide Gets A New Edition 09/24/2020
New Roadmap Aims to Transform Healthcare Landscape by… 08/13/2020